Cite
522 Targeting HER2 with trastuzumab-DM1 (T-DM1) is highly effective in preclinical models of HER2-overexpressing bladder cancer.
MLA
Hayashi, T., et al. “522 Targeting HER2 with Trastuzumab-DM1 (T-DM1) Is Highly Effective in Preclinical Models of HER2-Overexpressing Bladder Cancer.” European Urology Supplements, vol. 13, no. 1, Apr. 2014, p. e522. EBSCOhost, https://doi.org/10.1016/S1569-9056(14)60514-5.
APA
Hayashi, T., Jäger, W., Moskalev, I., Awrey, S., Li, N., Fazli, L., Yasui, W., Matsubara, A., & Black, P. C. (2014). 522 Targeting HER2 with trastuzumab-DM1 (T-DM1) is highly effective in preclinical models of HER2-overexpressing bladder cancer. European Urology Supplements, 13(1), e522. https://doi.org/10.1016/S1569-9056(14)60514-5
Chicago
Hayashi, T., W. Jäger, I. Moskalev, S. Awrey, N. Li, L. Fazli, W. Yasui, A. Matsubara, and P.C. Black. 2014. “522 Targeting HER2 with Trastuzumab-DM1 (T-DM1) Is Highly Effective in Preclinical Models of HER2-Overexpressing Bladder Cancer.” European Urology Supplements 13 (1): e522. doi:10.1016/S1569-9056(14)60514-5.